Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Guillain-Barre Syndrome Market Growth in 2025?
There has been robust growth in the guillain-barre syndrome market size over the past few years. The market, which is projected to expand from $0.60 billion in 2024 to $0.64 billion in 2025, will experience a compound annual growth rate (CAGR) of 5.9%. Factors such as increased demand for GBS treatments, growing instances of viral infections, escalating vaccination efforts worldwide, improved comprehension of autoimmune processes, and heightened awareness and diagnosis have contributed to the growth during the historical period.
What Is the Forecast for the Guillain-Barre Syndrome Market Size Through 2029?
Anticipated robust growth in the guillain-barre syndrome market over the upcoming years is predicted to increase its worth to $0.79 billion by 2029, with a compound annual growth rate (CAGR) of 5.6%. The predicted growth during the forecast period may be driven by factors such as a higher incidence of guillain-barre syndrome, amplified effects of climate change, escalating use of immunotherapies and medicine, advanced diagnostic capacities, and an increased occurrence of multifocal motor neuropathy. The forecast period is also noted for potential major trends including augmented diagnostic techniques, the design of immunoglobulin therapies, advancements in plasmapheresis protocols, gene therapy research, increased early intervention efforts, the discovery of novel prognostic biomarkers, and expanded clinical trials for innovative treatment strategies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp
What are the Key Market Players in Guillain-Barre Syndrome Market and How They’re Evolving?
Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, Thermo Fisher Scientific Inc., AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., Annexon Inc., Immunovant Inc., CSL Behring LLC, Hansa Biopharma AB, NeuLine Health Inc., Ridge Diagnostics Inc., Deymed Diagnostic LLC, VYVGART Hytrulo.
What Are the Primary Growth Drivers in the Guillain-Barre Syndrome Market?
The growth of the guillain-barre syndrome market is being propelled by the escalating risk of immunological diseases. These are conditions where the immune system either overperforms, underperforms or malfunctions leading to disorders such as allergies, immunodeficiencies or autoimmune diseases. Various factors such as environmental changes, lifestyle, better diagnosis methods, and genetic predisposition are contributing to the increase of immunological diseases. Guillain barré syndrome can be a consequence of these diseases as they can instigate an autoimmune response where the body’s immune system erroneously targets the peripheral nerves, resulting in inflammation and nerve damage. For example, a report by the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, stated in July 2024 that by the end of 2022, approximately 39.5 million people globally were afflicted with HIV, with 1.3 million new infections and 630,000 AIDS-related deaths reported that year. This number had increased to around 39.9 million by 2023. Consequently, the escalating risk of immunological diseases is fuelling the guillain-barre syndrome market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21198&type=smp
What Are the Leading Segments in the Global Guillain-Barre Syndrome Industry?
The guillain-barre syndrome market covered in this report is segmented –
1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), Other Types
2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics
3) By Route Of Administration: Parenteral, Oral
4) By End User: Hospitals, Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement
2) By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Progressive CIDP, Relapsing-Remitting CIDP, Multifocal CIDP
3) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia
4) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement
5) By Other Types: Acute Sensory Ganglionopathy, Variants With Cranial Nerve Involvement, Bickerstaff Brainstem Encephalitis
What Are the Key Market Trends in the Guillain-Barre Syndrome Industry?
Major players in the Guillain-Barre syndrome market are focusing their efforts on the development of innovative medications, such as monoclonal antibodies, to increase treatment effectiveness, cater to unmet medical needs, and broaden their market reach. Monoclonal antibodies, which are proteins synthetically produced in labs to specifically target antigens, play a key role in controlling immune responses and enhancing therapeutic results. For example, Annexon Inc., an American biopharmaceutical firm, was granted an orphan drug status by the European Medicines Agency (EMA) in October 2023 for its drug, ANX005, intended for treating Guillain-Barre syndrome (GBS). This monoclonal antibody, which targets C1q, has shown promising initial results in enhancing muscle strength and decreasing the necessity for ventilation as compared to IVIg, positioning it as a crucial step forward in therapy.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report
What Is the Regional Outlook for the Guillain-Barre Syndrome Market?
North America was the largest region in the guillain-barre syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21198
This Report Delivers Insight On:
1. How big is the guillain-barre syndrome market, and how is it changing globally?
2. Who are the major companies in the guillain-barre syndrome market, and how are they performing?
3. What are the key opportunities and risks in the guillain-barre syndrome market right now?
4. Which products or customer segments are growing the most in the guillain-barre syndrome market?
5. What factors are helping or slowing down the growth of the guillain-barre syndrome market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model